Sign In

Credits Offered

  • Continuing Medical Education (CME): 11.75 AMA PRA Category 1 Credits™

Accreditation and Designation Statements

Continuing Medical Education (CME)

The American Association for the Study of Liver Diseases (AASLD) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. AASLD designates this live activity for a maximum of 11.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Credits

Physicians and other health care professionals seeking 11.75 AMA PRA Category 1 Credits™ for this live continuing medical education activity must complete an evaluation by Friday, June 7, 2019. A link to the CME and MOC evaluation will be emailed to attendees after the conference.

Needs Statement

There are growing challenges to accurately predict drug-induced liver injury (DILI) risk tied to evolving immunotherapies and in patients with underlying chronic liver disease. This international academic-industry-government conference sponsored by the FDA and AASLD, will hear expert presentations on new treatments with hepatotoxic liability and discuss study populations of growing concern as well as many state-of-the-art scientific tools and methods that are now becoming available for the assessment of DILI risk. There will also be a robust exchange of ideas and debate towards establishing consensus among participants in the meeting as a prelude for a planned comprehensive revision of the seminal FDA guidance on the pre-marketing evaluation of DILI, issued 10 years ago.

Learning Objectives

  • Understand the means by which a diagnosis of DILI is established and the value and limitations of causality instruments, severity scales, liver histology and available diagnostic/ prognostic biomarkers.
  • How to assess DILI diagnosis and severity in patients with pre-existing liver disease
  • How to diagnose and manage patients who experience liver injury while receiving investigational immunotherapy for benign and malignant diseases

Target Audience

  • Hepatologists
  • Gastroenterologists
  • Pharmacists
  • Physician Assistants
  • Surgeons
  • Fellows/Trainees
  • Toxicologists
  • Pathologists
  • Basic Scientists
  • Pharmaceutical Developers
  • Government Regulators

This activity was planned in the context of the following ACGME/IOM/IPEC competencies:

  • Patient Care and Procedural Skills
  • Provide Patient-centered Care
  • Values/Ethics for Interprofessional Practice
  • Medical Knowledge
  • Work in Interdisciplinary Teams
  • Practice-based Learning and Improvement
  • Employ Evidence-based Practice
  • Teams and Teamwork
  • Professionalism
  • Utilize Informatics
  • Systems-based Practice